China SXT Pharmaceuticals Inc（SXTC）の財務SXTCChina SXT Pharmaceuticals Inc

China SXT Pharmaceuticals Inc (SXTC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Regular TCMP, accounting for 107.1% of total sales, equivalent to $547.84K. Other significant revenue streams include Others and Advanced TCMP. Understanding this composition is critical for investors evaluating how SXTC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, China SXT Pharmaceuticals Inc maintains a gross margin of 28.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -153.28%, while the net margin is 32.01%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SXTC converts its operational activities into shareholder value.

In the context of the broader market, SXTC competes directly with industry leaders such as BDRX and SPRC. With a market capitalization of $381.16K, it holds a significant position in the sector. When comparing efficiency, SXTC's gross margin of 28.74% stands against BDRX's N/A and SPRC's N/A. Such benchmarking helps identify whether China SXT Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows troubling signs, with a forward P/E of 0 and a price-to-sales ratio of 0.437, suggesting low valuation relative to sales but also highlighting the company's struggles to generate profit.